APP and myeloid sarcoma: So far little is known about the impact of APP-dependent gene-regulation via AICD in MS, but pharmacological treatment studies in an animal model of Alzheimer ́s disease suggest that disruption of nuclear action of the AICD could improve neurological symptoms [41].